SCHEMBL6843035

SCHEMBL6843035

CSc1ccc(-c2ccc(Br)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
ALDH1A1 P00352 3/20 0.48
MAPK1 P28482 1/20 0.48
CYP2A6 P11509 1/20 0.42
PTGS2 P35354 3/20 0.41
HAO1 Q9UJM8 1/20 0.40
NISCH Q9Y2I1 1/20 0.39
MAOA P21397 2/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A3 Q01959 1/20 0.39
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116401 0.92
SCHEMBL8588523 0.89 CYP2A6 (0.47) LMNAALDH1A1CYP2A6MAOASLC6A4
SCHEMBL10528160 0.86 ALDH1A1 (0.50) ALDH1A1PTGS2HAO1NISCHMAOA
SCHEMBL10300271 0.86 ALDH1A1 (0.50) ALDH1A1PTGS2HAO1NISCHMAOA
SCHEMBL3954756 0.78 CYP1A1 (0.59) ALDH1A1
SCHEMBL3954754 0.78 CYP1A1 (0.59) ALDH1A1
SCHEMBL22167328 0.78 SLC6A4 (0.54) LMNAALDH1A1CYP2A6PTGS2MAOA
SCHEMBL970462 0.78 ALDH1A1 (0.48) LMNAALDH1A1MAPK1PTGS2
SCHEMBL943735 0.78 ALDH1A1 (0.52) ALDH1A1MAPK1CYP2A6HAO1MAOA
SCHEMBL8588228 0.78 MAOA (0.56) LMNAALDH1A1MAPK1CYP2A6HAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371400-B2 Cathepsin inhibitors ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2025-07-29 US disclosed
US-20240182409-A1 CATHEPSIN INHIBITORS ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2024-06-06 US disclosed
US-11820734-B2 Cathepsin inhibitors ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2023-11-21 US disclosed
EP-4046987-A1 CATHEPSIN INHIBITORS Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) (NL) 2022-08-24 EP disclosed
US-20220227705-A1 CATHEPSIN INHIBITORS ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2022-07-21 US disclosed
EP-3720840-B1 CATHEPSIN INHIBITORS ACADEMISCH ZIEKENHUIS LEIDEN (NL) 2022-01-19 EP disclosed
US-11174224-B2 Cathepsin inhibitors ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2021-11-16 US disclosed
US-11174224-B2 Cathepsin inhibitors ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2021-11-16 US disclosed
CN-108912020-B Preparation method of Orobactit and intermediate thereof 上海博志研新药物技术有限公司 2021-05-28 CN disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
US-20200385341-A1 CATHEPSIN INHIBITORS ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2020-12-10 US disclosed
US-20200385341-A1 CATHEPSIN INHIBITORS ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2020-12-10 US disclosed
EP-3720840-A1 CATHEPSIN INHIBITORS Academisch Ziekenhuis Leiden h.o.d.n. LUMC (NL) 2020-10-14 EP disclosed
WO-2019112426-A1 CATHEPSIN INHIBITORS ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2019-06-13 WO disclosed
WO-2013002514-A2 ORGANIC ELECTROLUMINESCENCE DEVICE USING DIARYLAMINE DERIVATIVES, AND NOVEL COMPOUND AND COMPOSITION FOR ORGANIC ELECTROLUMINESCENCE DEVICE 덕산하이메탈(주) (KR) 2013-01-03 WO disclosed
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820734-B2 Cathepsin inhibitors CTSK, CTSZ, CTSF LMNA 2792/4885ALDH1A1 3238/4885MAPK1 3538/4885
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors TNF, MMP9, MMP1 LMNA 2725/4885ALDH1A1 440/4885MAPK1 267/4885
US-12371400-B2 Cathepsin inhibitors CTSK, CTSZ, CTSF LMNA 2792/4885ALDH1A1 3238/4885MAPK1 3538/4885
US-20200385341-A1 CATHEPSIN INHIBITORS CTSK, CTSZ, CTSF LMNA 2792/4885ALDH1A1 3238/4885MAPK1 3538/4885
US-11174224-B2 Cathepsin inhibitors CTSK, CTSZ, CTSF LMNA 2792/4885ALDH1A1 3238/4885MAPK1 3538/4885
US-20220227705-A1 CATHEPSIN INHIBITORS CTSK, CTSZ, CTSF LMNA 2792/4885ALDH1A1 3238/4885MAPK1 3538/4885
US-20240182409-A1 CATHEPSIN INHIBITORS CTSK, CTSZ, CTSF LMNA 2792/4885ALDH1A1 3238/4885MAPK1 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.